Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

University of Edinburgh and Selcia in £2.5 m Bid

Published: Tuesday, February 04, 2014
Last Updated: Monday, February 03, 2014
Bookmark and Share
Edinburgh University and Selcia research new drugs to combat sleeping sickness disease.

An initiative is under way to develop new drugs for a devastating tropical disease that threatens almost 70 million people in Africa.

Scientists are beginning a £2.5 million project to design novel treatments for sleeping sickness, which is spread by the bite of the tsetse fly and is prevalent in west and central Africa. It can damage the nervous system and cause coma, organ failure and death.

Existing medicines for the disease can cause debilitating side-effects or can be fatal. Some drugs must be administered using a drip, which makes treatment time-consuming and expensive. Researchers hope to develop safe, effective medicines that can be given easily.

The quest for new treatments will build on previous studies about how the infection occurs. Scientists have shown that the parasite is able to survive in the bloodstream by using enzymes to convert blood sugars into the energy it needs to stay alive. They have identified potential drug compounds that can stop two of these enzymes from functioning, so killing the parasite.

Scientists from the University of Edinburgh, working with the international life sciences contract research organization Selcia, will design and develop drugs based on these drug compounds. Their aim is to design a drug that will be effective in small doses, and will work even on advanced infections. The 30-month project, funded by the Wellcome Trust, will seek to test the compounds in the lab and in mice, ahead of further studies that could involve human trials.

New treatments could be developed into veterinary medicines for infections caused by the same parasite in livestock, which cost farmers about US$2 billion a year.

Professor Malcolm Walkinshaw, of the University of Edinburgh’s School of Biological Sciences, said: “Sleeping sickness is a widespread, neglected disease which, if left untreated, is invariably fatal and drugs are poorly effective. We hope to develop new forms of treatment that can be easily administered and will eventually help curb the disease’s impact.”

Dr Hans Fliri, Chairman and CEO of Selcia, said: “We are delighted to collaborate with the University of Edinburgh’s School of Biological Sciences. Selcia has made no secret of its determination to develop strong links with academic research teams. We see these partnerships as a key strategic element of our growing integrated drug discovery offer.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selcia Appoints New Director of Discovery
Appointment of John Davis to the role of Director of Discovery.
Wednesday, October 09, 2013
Selcia Granted Patent for CEfrag™ Drug Discovery Platform
CEfrag™ platform uses capillary electrophoresis to identify fragment compounds.
Friday, September 21, 2012
Selcia Celebrates 20 Years Radiolabelling Landmark
Radiolabelling division is expected to grow by a third within the next five years.
Monday, June 11, 2012
Selcia and Heptares Therapeutics Announce New Fragment Screening Collaboration
Partnership to utilize Selcia’s CEfrag™ capillary electrophoresis fragment screening technology.
Thursday, April 19, 2012
Simon Bury Joins Selcia
Selcia Limited announces the appointment of Simon Bury as Business Development Director of its Discovery division, to lead expansion plans in its drug discovery offering.
Friday, June 03, 2011
Selcia Awarded GMP Certificate for Preparation and Carbon-14 Labelling of APIs for Clinical Trials
Extended capability expected to shorten the timeframe for commencement of client’s key Phase 1 clinical trials.
Thursday, December 09, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!